CSIR-CDRI screens 2654 compounds for various disease profiling: Govt
MoES has identified a potent anti-cancer molecule named GS/IICT5/6
Union Minister of State, PMO, Personnel, Public Grievances, Pensions, Minister of State (Independent Charge) Science & Technology, M/o Earth Sciences; MoS, Atomic Energy and Space, Dr Jitendra Singh said that a total of 2654 compounds were screened for different activities for anti-cancer, anti-angiogenic, anti-inflammatory, anti-bacterial, and GPCR profiling by CSIR-Central Drug Research Institute, the nodal lab for MoES.
In a written reply to a question in Lok Sabha Dr Singh said that specifically for anticancer activity of compounds submitted through MoES programme was evaluated on five different cancer-type cell lines (MDA-MB231, DLD-1, FaDu, HeLa, and A549) as per standard operating protocol (SOP).
The minister further said that with the above endeavour, MoES has identified a potent anti-cancer molecule named GS/IICT5/6, the molecule has shown a better tumour inhibitory profile as compared to Sunitinib. Currently, the molecule has cleared the initial safety profile. The molecule will be evaluated further.
Dr Singh also said that on similar lines Cancer patients suffer from neuropathic pain after chemotherapy. For relieving the patient suffering using the MoES programme, the Ministry has discovered a novel compound SB/CDRI4/105 that can alleviate chemotherapy-induced peripheral neuropathic pain. Currently, the molecule is also in the advanced stages of lead optimisation and IND-enabling studies will be enabled shortly.
The minister said that a potent molecule SP/NISER29, a new class drug having anti-cancer activity has been identified. The molecule has shown potent anti-tumour activity in the animal model better than taxol. The compound has very good stability and disrupts the cytoskeletal filaments.